This new CPB states that (i) Luxturna (voretigene neparvovec-rzyl) is considered medically necessary for the treatment of individuals with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy when selection criteria are met; and (ii) repeat administration of Luxturna in the same eye is considered experimental and investigational.